Research library
Sources, with the status on the record.
Each row is a paper or a ClinicalTrials.gov entry checked on 21 November 2026. Titles are the authors’ or the registry’s words. Nalen Lab does not restate them as claims about these products. A registration is not a result.
Records checked 2026-11-21. Open registry rows in this view: 0. Selank has published papers and no verified intervention trial.
Loading filters…
Retatrutide
2023
Publication
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM et al. · New England Journal of Medicine
PublishedSame compound as the catalogue listing
Phase 2 trial. The title is the authors' wording. A registration is not implied by this paper.
View in the catalogue